Delivery Order SPE2DB24D6041-SPE2DB25FKCJJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,137.56 to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Telmisartan 40 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $3,555.12. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.99 billion and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count) under a firm fixed-price contract valued at $1,344.40. The award was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. This delivery order represents a non-set-aside competitive award and is part of a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) relationship with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $5,608.29 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Telmisartan 20 mg tablets in quantities of 30 units, with an ultimate completion date of July 30, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-HCZ 80-25 mg tablets (unit dose, 30-count packages) valued at $3,031.71. This non-set-aside, competitively awarded delivery order, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a firm fixed-price pharmaceutical supply transaction supporting federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Telmisartan 40 mg tablets. The contract has a firm-fixed price of $1,355.12 and an ultimate completion date of August 21, 2024. AmerisourceBergen has been awarded this delivery order as part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which enables...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of Telmisartan 40 mg tablets, a pharmaceutical product, with a ceiling value of $1,162.01. The contract is a firm fixed price, non-set-aside agreement with an ultimate completion date of April 10, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division located in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Telmisartan 80 mg tablets (30-count packages) under a firm fixed-price contract valued at $3,808.62. This competitive award, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a child delivery order executed against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is located at the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Telmisartan 80 mg tablets (30-count package) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract carries a ceiling value of $1,270.22 and represents a non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of Telmisartan 40 mg tablets, a prescription medication, to support U.S. military treatment programs and facilities. The contract is a firm fixed price delivery order with a ceiling value of $5,804.89 and a performance period through...
- SPE2DB24D6041Indefinite Delivery Contract
- SPE2DB24D6041-SPE2DB25FKCJJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,262.33 to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count) on July 29, 2025, with completion scheduled for July 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical federal medical procurement vendor, particularly for Department of Defense and veteran healthcare systems. The parent IDC encompasses the supply of a broad range of pharmaceutical products and medical commodities across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates consistent capability to fulfill diverse medical supply requirements through competitive procurement processes, with the DLA planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts across multiple regions to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 7/29/25 |